Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Puberty‐Promoting Treatment and Psychosocial Well‐Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial

Kariola, Laura; Varimo, Tero; Laaperi, Mitja; Huopio, Hanna; Tenhola, Sirpa; Voutilainen, Raimo; Toppari, Jorma; Kosola, Silja; Miettinen, Päivi J.; Raitakari, Olli; Elovainio, Marko; Raivio, Taneli; Hero, Matti

Puberty‐Promoting Treatment and Psychosocial Well‐Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial

Kariola, Laura
Varimo, Tero
Laaperi, Mitja
Huopio, Hanna
Tenhola, Sirpa
Voutilainen, Raimo
Toppari, Jorma
Kosola, Silja
Miettinen, Päivi J.
Raitakari, Olli
Elovainio, Marko
Raivio, Taneli
Hero, Matti
Katso/Avaa
Clinical Endocrinology - 2025 - Kariola - Puberty‐Promoting Treatment and Psychosocial Well‐Being in Boys With.pdf (661.4Kb)
Lataukset: 

Wiley
doi:10.1111/cen.70039
URI
https://doi.org/10.1111/cen.70039
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe202601216107
Tiivistelmä

Objective: In boys, constitutional delay of growth and puberty (CDGP) has been associated with diverse negative psychosocial effects. Albeit alleviating distress is one of the main reasons for inducing pubertal development, the impact of puberty-promoting treatment on psychosocial wellbeing is under-researched. Our objective was to investigate the impact of puberty-promoting therapies on the behavioural patterns as defined by the temperament characteristics emotionality, activity, and sociability (EAS) in boys with CDGP.

Design: The study is a randomized, controlled, open-label trial.

Patients: Thirty boys were randomized to receive either aromatase inhibitor letrozole (2.5 mg/day) (n = 15) or intramuscular testosterone (1 mg/kg/every 4 weeks) (n = 15) for 6 months and followed up to 12 months. To compare our results with healthy peers, an age- and postal-code matched, and a national reference population were collected.

Measurements: Temperament characteristics were evaluated with a standardized and validated questionnaire at 0-, 6-, and 12-month visits.

Results: In comparison to local peers, boys with CDGP were more withdrawn (p = 0.02) and experienced less anger (p = 0.02) and fear (p = 0.02). Compared to both local and national controls, there was a significant difference in emotionality, CDGP boys being less negatively emotional than peers (p = 0.04). Sociability was higher in the Lz-group in comparison to the T-group both after the 6-month treatment period (-0.48, 95% CI: 0.89; -0.08, p = 0.019) and at 12-month follow-up (-0.72, CI: 95%, -1.12; -0.32, p = 0.001).

Conclusion: Overall, boys with CDGP exhibited a generally docile temperament. The administration of puberty-promoting treatments did not result in any adverse psychosocial effects on the temperament characteristics assessed.

Kokoelmat
  • Rinnakkaistallenteet [29337]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste